AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 9710861 — intervention group
Group type: EXPERIMENTAL
Intervention: VO2 < 18 mL.kg-1.min-1
Number of subjects: 161
Study 9710861 — intervention group
Group type: EXPERIMENTAL
Intervention: Peak VO2 included in PF model
Number of subjects: 161
Study 1836989 — intervention group
Group type: EXPERIMENTAL
Intervention: 26 G spinal needle
Number of subjects: 284
Study 1836989 — intervention group
Group type: COMPARATOR
Intervention: 22 G spinal needle
Number of subjects: 284
Study 1836989 — intervention group
Group type: EXPERIMENTAL
Intervention: 4.5 g iodine
Number of subjects: 284
Study 1836989 — intervention group
Group type: EXPERIMENTAL
Intervention: Operator experience
Number of subjects: 284
Study 1836989 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrospinal fluid leakage
Number of subjects: 284
Study 7035046 — intervention group
Group type: EXPERIMENTAL
Intervention: Colostrum feeding
Number of subjects: 180
Study 7035046 — intervention group
Group type: COMPARATOR
Intervention: Glucose water feeding
Number of subjects: 180
Study 30894408 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-based developmental screening and care coordination through 2-1-1
Number of subjects: 152
Study 30894408 — intervention group
Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 152
Study 27838447 — intervention group
Group type: EXPERIMENTAL
Intervention: Anodal-tDCS (a-tDCS) targeting the left dorsolateral prefrontal cortex (DLPFC) for 20 minutes at 2mA current intensity
Number of subjects: 17
Study 27838447 — intervention group
Group type: COMPARATOR
Intervention: Sham-tDCS (placebo) with the same electrode position but stimulator turned off after 30 seconds
Number of subjects: 17
Study 26699739 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine-fentanyl (DF)
Number of subjects: 60
Study 26699739 — intervention group
Group type: COMPARATOR
Intervention: Midazolam-fentanyl (MF)
Number of subjects: 60
Study 24332248 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (LD ASA)
Number of subjects: 23336
Study 24332248 — intervention group
Group type: COMPARATOR
Intervention: High-dose aspirin (HD ASA)
Number of subjects: 23336
Study 24332248 — intervention group
Group type: COMPARATOR
Intervention: Study site variability
Number of subjects: 23336
Study 24332248 — intervention group
Group type: COMPARATOR
Intervention: Median odds ratio comparing sites
Number of subjects: 23336
Study 22613433 — intervention group
Group type: EXPERIMENTAL
Intervention: Transumbilical single‐port laparoscopic hysterectomy (TSPLH)
Number of subjects: 108
Study 22613433 — intervention group
Group type: COMPARATOR
Intervention: Traditional four‐port total laparoscopic hysterectomy (TLH)
Number of subjects: 108
Study 20105036 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 weeks of Integrative Body‐Mind Training (IBMT)
Number of subjects: 35
Study 20105036 — intervention group
Group type: COMPARATOR
Intervention: Relaxation control
Number of subjects: 35
Study 18700219 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioural therapy (CBT)
Number of subjects: 150
Study 18700219 — intervention group
Group type: COMPARATOR
Intervention: Structured care
Number of subjects: 150
Study 15972866 — intervention group
Group type: EXPERIMENTAL
Intervention: ChAglyCD3
Number of subjects: 80
Study 15972866 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 80
Study 12870262 — intervention group
Group type: EXPERIMENTAL
Intervention: Permissive hypercapnia (up to 45 mmHg, Group I, n = 17)
Number of subjects: 33
Study 12870262 — intervention group
Group type: COMPARATOR
Intervention: Intervention to ensure mild hypocapnia (around 33 mmHg, Group II, n = 16)
Number of subjects: 33
Study 12870262 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 33
Study 10231869 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of growth hormone (GH) and low-dose estrogen (ethinyl estradiol, 5 micrograms/d) in girls with Turner syndrome.
Number of subjects: 11
Study 10231869 — intervention group
Group type: COMPARATOR
Intervention: Growth hormone (GH) alone in girls with Turner syndrome.
Number of subjects: 11
Study 10231869 — intervention group
Group type: COMPARATOR
Intervention: Estrogen (ethinyl estradiol, 50 micrograms/d) and progesterone in adult females with Turner syndrome.
Number of subjects: 11
Study 10231869 — intervention group
Group type: COMPARATOR
Intervention: Growth hormone (GH) alone in adults with Turner syndrome.
Number of subjects: 11
Study 10231869 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen (ethinyl estradiol, 50 micrograms/d) and progesterone in combination with GH in adults.
Number of subjects: 11
Study 9193221 — intervention group
Group type: EXPERIMENTAL
Intervention: Induction chemotherapy (cisplatin and fluorouracil) plus radiation therapy
Number of subjects: 44
Study 9193221 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 immunohistochemistry
Number of subjects: 44
Study 9193221 — intervention group
Group type: EXPERIMENTAL
Intervention: p53 mutations
Number of subjects: 44
Study 1493838 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine 60 mg once daily
Number of subjects: 12
Study 1493838 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 3554553 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine (2 mg in 5 ml saline, repeated on demand)
Number of subjects: 33
Study 3554553 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine (10 mg on request)
Number of subjects: 33
Study 3554553 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural morphine
Number of subjects: 33
Study 3554553 — intervention group
Group type: COMPARATOR
Intervention: Intramuscular morphine
Number of subjects: 33
Study 30149366 — intervention group
Group type: EXPERIMENTAL
Intervention: nab‐paclitaxel, gemcitabine, cisplatin and oral capecitabine (PAXG; arm A; N = 26)
Number of subjects: 54
Study 30149366 — intervention group
Group type: COMPARATOR
Intervention: nab‐paclitaxel followed by gemcitabine (AG; arm B; N = 28)
Number of subjects: 54
Study 30149366 — intervention group
Group type: EXPERIMENTAL
Intervention: PAXG
Number of subjects: 54
Study 30149366 — intervention group
Group type: COMPARATOR
Intervention: AG
Number of subjects: 54
Study 27936949 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine (CCB)
Number of subjects: 76
Study 27936949 — intervention group
Group type: COMPARATOR
Intervention: Valsartan (ARB)
Number of subjects: 76
Study 25471910 — intervention group
Group type: COMPARATOR
Intervention: No brace
Number of subjects: 60
Study 25471910 — intervention group
Group type: EXPERIMENTAL
Intervention: Soft brace
Number of subjects: 60
Study 25471910 — intervention group
Group type: EXPERIMENTAL
Intervention: Rigid brace
Number of subjects: 60
Study 25471910 — intervention group
Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 60
Study 22582765 — intervention group
Group type: EXPERIMENTAL
Intervention: Individual cognitive-behavioral therapy (I-CBT)
Number of subjects: 75
Study 22582765 — intervention group
Group type: COMPARATOR
Intervention: Wait-list control (WL)
Number of subjects: 75
Study 20101189 — intervention group
Group type: EXPERIMENTAL
Intervention: tesamorelin (2 mg SC every day)
Number of subjects: 404
Study 20101189 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 404
Study 17545008 — intervention group
Group type: EXPERIMENTAL
Intervention: Novel immunosuppressive agents and established immunosuppressive agents
Number of subjects: 0
Study 17545008 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcineurin inhibitors
Number of subjects: 0
Study 17545008 — intervention group
Group type: EXPERIMENTAL
Intervention: Newer immunosuppressive agents (proliferation signal inhibitors)
Number of subjects: 0
Study 17545008 — intervention group
Group type: EXPERIMENTAL
Intervention: Costimulatory pathway inhibitors and other new immunosuppressive agents
Number of subjects: 0
Study 16213136 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravaginal micronised progesterone 200 mg three times daily (n=351)
Number of subjects: 430
Study 16213136 — intervention group
Group type: COMPARATOR
Intervention: Oral dydrogesterone 10 mg twice daily (n=79)
Number of subjects: 430
Study 12360598 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 40 mg/day for 8 weeks
Number of subjects: 117
Study 12360598 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 8 weeks
Number of subjects: 117
Study 9952057 — intervention group
Group type: EXPERIMENTAL
Intervention: Trazodone
Number of subjects: 78
Study 9952057 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium Valproate
Number of subjects: 78
Study 9952057 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 78
Study 8536446 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol 50 micrograms/norethindrone 1 mg
Number of subjects: 3
Study 8536446 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol 35 micrograms/norethindrone 1 mg
Number of subjects: 3
Study 8536446 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethinyl estradiol 35 micrograms/norethindrone 0.5 mg
Number of subjects: 3
Study 2029857 — intervention group
Group type: EXPERIMENTAL
Intervention: Cocaine abuse among heroin addicts
Number of subjects: 0
Study 7348567 — intervention group
Group type: EXPERIMENTAL
Intervention: CMFH (CMF plus fluoxymesterone)
Number of subjects: 0
Study 7348567 — intervention group
Group type: COMPARATOR
Intervention: CMF (cyclophosphamide, methotrexate, and fluorouracil)
Number of subjects: 0
Study 31679079 — intervention group
Group type: COMPARATOR
Intervention: Platelet aggregation in men with diabetes mellitus
Number of subjects: 720
Study 31679079 — intervention group
Group type: COMPARATOR
Intervention: Coronary artery calcification (CAC) in men with diabetes mellitus
Number of subjects: 720
Study 30973949 — intervention group
Group type: EXPERIMENTAL
Intervention: Severe maternal ACA
Number of subjects: 193
Study 28027641 — intervention group
Group type: EXPERIMENTAL
Intervention: Wolfberry Extract (WBE) - 13.5 g in 80 mL pouch, consumed after one meal per day for 8 weeks
Number of subjects: 53
Study 28027641 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 26604028 — intervention group
Group type: EXPERIMENTAL
Intervention: Graded Motor Imagery (GMI)
Number of subjects: 6
Study 26604028 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural Mobilization (NM)
Number of subjects: 6
Study 23570290 — intervention group
Group type: EXPERIMENTAL
Intervention: DSL v5 prescription
Number of subjects: 16
Study 23570290 — intervention group
Group type: COMPARATOR
Intervention: NAL‐NL1 prescription
Number of subjects: 16
Study 22122291 — intervention group
Group type: EXPERIMENTAL
Intervention: Children's appetite awareness training
Number of subjects: 36
Study 22122291 — intervention group
Group type: EXPERIMENTAL
Intervention: Cue exposure treatment-food
Number of subjects: 36
Study 22122291 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments
Number of subjects: 36
Study 19726540 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil plus streptozotocin (day 1-5)
Number of subjects: 64
Study 19726540 — intervention group
Group type: COMPARATOR
Intervention: recombinant IFN-alpha-2a (3 MU x 3 per week)
Number of subjects: 64
Study 17854593 — intervention group
Group type: EXPERIMENTAL
Intervention: Norfloxacin
Number of subjects: 68
Study 17854593 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study 18210717 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed drug combination RMP300 HIN150 (20 patients)
Number of subjects: 38
Study 18210717 — intervention group
Group type: COMPARATOR
Intervention: Single drug tablets (RMP and HIN) (18 patients)
Number of subjects: 38
Study 18210717 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (20 patients with fixed drug combination and 18 patients with single drug tablets)
Number of subjects: 38
Study 11483169 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial language tasks (naming tasks)
Number of subjects: 0
Study 11483169 — intervention group
Group type: EXPERIMENTAL
Intervention: Spatial memory tasks
Number of subjects: 0
Study 11483169 — intervention group
Group type: EXPERIMENTAL
Intervention: Relationship between spatial language and spatial memory
Number of subjects: 0
Study 9710018 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI signal abnormalities on T2-weighted images (T2-WI)
Number of subjects: 75
Study 9710018 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI signal abnormalities on T1-weighted images (T1-WI)
Number of subjects: 75
Study 9710018 — intervention group
Group type: EXPERIMENTAL
Intervention: Severity scores of hyperintensities
Number of subjects: 75
Study 9710018 — intervention group
Group type: EXPERIMENTAL
Intervention: Comparison of symptomatic vs asymptomatic gene carriers
Number of subjects: 75
Study 9710018 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of dementia or Rankin score > 1
Number of subjects: 75
Study 7803946 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment (specifics not detailed, but mentions diuretics and beta-adrenergic blocking drugs)
Number of subjects: 0
Study 7803946 — intervention group
Group type: COMPARATOR
Intervention: Antihypertensive treatment (ACE inhibitors and calcium channel blockers)
Number of subjects: 0
Study 2468858 — intervention group
Group type: COMPARATOR
Intervention: Nifedipine 10 mg (acute oral administration)
Number of subjects: 20
Study 2468858 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrendipine 10 mg b.i.d. (chronic oral administration)
Number of subjects: 20
Study 31790147 — intervention group
Group type: EXPERIMENTAL
Intervention: N-terminal B-type natriuretic peptide (NT-proBNP) screening and ECG recordings
Number of subjects: 6878
Study 31790147 — intervention group
Group type: COMPARATOR
Intervention: Control group (no screening)
Number of subjects: 6878
Study 29107569 — intervention group
Group type: EXPERIMENTAL
Intervention: School support intervention (school uniforms, tuition payment, nurse visits)
Number of subjects: 835
Study 29107569 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 835
Study 28063325 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo NRT sampling (patch, gum, combination NRT)
Number of subjects: 43
Study 28063325 — intervention group
Group type: EXPERIMENTAL
Intervention: In vivo NRT sampling
Number of subjects: 43
Study 28063325 — intervention group
Group type: COMPARATOR
Intervention: Standard smoking cessation with cNRT
Number of subjects: 43
Study 25051390 — intervention group
Group type: EXPERIMENTAL
Intervention: Caffeinated energy drink (3 mg·kg of caffeine)
Number of subjects: 13
Study 23541416 — intervention group
Group type: EXPERIMENTAL
Intervention: GnRH antagonist (ganirelix 0.25mg daily)
Number of subjects: 35
Study 23541416 — intervention group
Group type: COMPARATOR
Intervention: Natural control cycle
Number of subjects: 35
Study 20716145 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan (Aml/Val) combination therapy, low dose (2.5/80 mg, titrated to 5/160 mg or 10/160 mg)
Number of subjects: 1246
Study 20716145 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan (Aml/Val) combination therapy, high dose (5/80 mg, titrated to 5/160 mg or 10/160 mg)
Number of subjects: 1246
Study 20716145 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan (Aml/Val) combination therapy with optional hydrochlorothiazide (HCTZ) 12.5 mg
Number of subjects: 1246
Study 20716145 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan (Aml/Val) combination therapy, low dose
Number of subjects: 1246
Study 20716145 — intervention group
Group type: EXPERIMENTAL
Intervention: Amlodipine/valsartan (Aml/Val) combination therapy, high dose
Number of subjects: 1246
Study 18156922 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial iodine-131-labeled lipiodol (1850 MBq dose)
Number of subjects: 43
Study 18156922 — intervention group
Group type: COMPARATOR
Intervention: No adjuvant treatment (control)
Number of subjects: 43
Study 15716559 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal analgesia
Number of subjects: 750
Study 15716559 — intervention group
Group type: COMPARATOR
Intervention: Systemic analgesia
Number of subjects: 750
Study 12911824 — intervention group
Group type: EXPERIMENTAL
Intervention: Serrapeptase (SER) 30 mg/day for 4 weeks
Number of subjects: 29
Study 10423656 — intervention group
Group type: EXPERIMENTAL
Intervention: Nebivolol 5 mg
Number of subjects: 0
Study 10423656 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg
Number of subjects: 0
Study 10423656 — intervention group
Group type: COMPARATOR
Intervention: Both drugs
Number of subjects: 0
Study 8910932 — intervention group
Group type: EXPERIMENTAL
Intervention: LCP group (n = 13)
Number of subjects: 35
Study 8910932 — intervention group
Group type: COMPARATOR
Intervention: NO‐LCP group (n = 15)
Number of subjects: 35
Study 8910932 — intervention group
Group type: EXPERIMENTAL
Intervention: Human milk group (n = 7)
Number of subjects: 35
Study 1879595 — intervention group
Group type: EXPERIMENTAL
Intervention: Micronized progesterone
Number of subjects: 44
Study 1879595 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 7421183 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-relaxation therapy (30 1-hour training sessions over a 13-week period)
Number of subjects: 11
Study 7421183 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback-relaxation therapy (after 3 months of control)
Number of subjects: 11
Study 7421183 — intervention group
Group type: EXPERIMENTAL
Intervention: Biofeedback-relaxation therapy
Number of subjects: 11
Study 31430226 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrotinib (400 mg orally once per day) combined with capecitabine (1,000 mg/m2 orally twice per day on days 1 to 14)
Number of subjects: 128
Study 31430226 — intervention group
Group type: COMPARATOR
Intervention: Lapatinib (1,250 mg orally once per day) combined with capecitabine (1,000 mg/m2 orally twice per day on days 1 to 14)
Number of subjects: 128
Study 31430226 — intervention group
Group type: EXPERIMENTAL
Intervention: Pyrotinib
Number of subjects: 128
Study 28489889 — intervention group
Group type: EXPERIMENTAL
Intervention: Ascaris lumbricoides infection
Number of subjects: 2194
Study 28489889 — intervention group
Group type: EXPERIMENTAL
Intervention: Necator americanus infection
Number of subjects: 2194
Study 28489889 — intervention group
Group type: EXPERIMENTAL
Intervention: Any STH infection
Number of subjects: 2194
Study 26130342 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigated 'femur-first' THA
Number of subjects: 135
Study 26130342 — intervention group
Group type: COMPARATOR
Intervention: Conventional THA
Number of subjects: 135
Study 26130342 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 135
Study 23448616 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor (450 mg single dose, 180 mg 12 hours later, twice daily for 2 days, and once on day 4)
Number of subjects: 30
Study 23448616 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 30
Study 23448616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 21784734 — intervention group
Group type: EXPERIMENTAL
Intervention: E(2)V/DNG
Number of subjects: 231
Study 21784734 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 231
Study 19764168 — intervention group
Group type: EXPERIMENTAL
Intervention: Hollow earmold with vent diameters of 0, 1, 2, and 3 mm
Number of subjects: 8
Study 19764168 — intervention group
Group type: COMPARATOR
Intervention: Solid earmold with vent diameters of 0, 1, 2, and 3 mm
Number of subjects: 8
Study 17204037 — intervention group
Group type: EXPERIMENTAL
Intervention: BOD POD FRC measurement
Number of subjects: 92
Study 17204037 — intervention group
Group type: COMPARATOR
Intervention: BOD POD FRC trial #1 measurement
Number of subjects: 92
Study 15169685 — intervention group
Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 481
Study 15169685 — intervention group
Group type: EXPERIMENTAL
Intervention: NK(3) antagonist (SR142801)
Number of subjects: 481
Study 15169685 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐HT(2A/2C) antagonist (SR46349B)
Number of subjects: 481
Study 15169685 — intervention group
Group type: EXPERIMENTAL
Intervention: CB(1) antagonist (SR141716)
Number of subjects: 481
Study 15169685 — intervention group
Group type: EXPERIMENTAL
Intervention: NTS(1) antagonist (SR48692)
Number of subjects: 481
Study 11821367 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse visits over 6 months with blood pressure checks and negotiated lifestyle changes
Number of subjects: 718
Study 11821367 — intervention group
Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 718
Study 11821367 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse visits
Number of subjects: 718
Study 9723827 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan (50 mg once daily)
Number of subjects: 177
Study 9723827 — intervention group
Group type: COMPARATOR
Intervention: Captopril (25 mg twice daily)
Number of subjects: 177
Study 7979745 — intervention group
Group type: EXPERIMENTAL
Intervention: Lungs inflated during sternotomy
Number of subjects: 126
Study 7979745 — intervention group
Group type: COMPARATOR
Intervention: Lungs deflated during sternotomy
Number of subjects: 126
Study 7979745 — intervention group
Group type: EXPERIMENTAL
Intervention: Sternotomy starting at the xiphoid
Number of subjects: 126
Study 7979745 — intervention group
Group type: COMPARATOR
Intervention: Sternotomy starting at the sternal notch
Number of subjects: 126
Study 2566824 — intervention group
Group type: COMPARATOR
Intervention: Chloramphenicol
Number of subjects: 220
Study 2566824 — intervention group
Group type: EXPERIMENTAL
Intervention: Ampicillin
Number of subjects: 220
Study 2566824 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefotaxime
Number of subjects: 220
Study 2566824 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftriaxone
Number of subjects: 220
Study 1201184 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium supplements
Number of subjects: 8
Study 1201184 — intervention group
Group type: COMPARATOR
Intervention: Prednisone (without potassium supplements)
Number of subjects: 8
Study 30421547 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based interoceptive exposure task (MIET)
Number of subjects: 100
Study 30421547 — intervention group
Group type: EXPERIMENTAL
Intervention: Distraction instructions
Number of subjects: 100
Study 30421547 — intervention group
Group type: COMPARATOR
Intervention: No instructions (control group)
Number of subjects: 100
Study 29072163 — intervention group
Group type: EXPERIMENTAL
Intervention: Low glycemic index breakfast
Number of subjects: 10